The Effect of Regular Colchicine Treatment on Biomarkers Related with Vascular Injury in Newly Diagnosed Patients with Familial Mediterranean Fever

SARI İ., Yuksel A., Kozaci D., Selcuk S., Gokce G., Yildiz Y., ...More

INFLAMMATION, vol.35, no.3, pp.1191-1197, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 35 Issue: 3
  • Publication Date: 2012
  • Doi Number: 10.1007/s10753-012-9428-7
  • Journal Name: INFLAMMATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1191-1197
  • Keywords: familial Mediterranean fever, inflammation, cell adhesion molecules, intercellular adhesion molecule-1, melanoma cell adhesion molecule, plasminogen activator inhibitor-1 and human fetuin-A, FETUIN-A, RHEUMATIC-DISEASES, ADHESION MOLECULES, ENDOTHELIAL-CELLS, ATHEROSCLEROSIS, ASSOCIATION, RISK, INFLAMMATION, EXPRESSION, SELECTINS
  • Dokuz Eylül University Affiliated: Yes

Abstract

We aimed to evaluate some of the vascular biomarkers in newly diagnosed, colchicine naive familial Mediterranean fever (FMF) patients. Our primary aim was to investigate the effect of regular colchicine treatment on these variables. Twenty-four (12 males [M] and 12 females [F], 33.3 +/- 13.4 years) newly diagnosed FMF patients were included in the study. These patients were started on colchicine treatment following the initial assessment and were studied again no earlier than 2 months. Five patients were lost to follow-up, and assessment of the on-treatment patients was performed on the remaining 19 patients (8 M and 11 F, 33.6 +/- 11.8 years). There were 19 healthy subjects (11 M and 8 F, 32.2 +/- 7.2 years) who served as a control group. Cellular adhesion molecules (CAMs; soluble intercellular adhesion molecule-1 [sICAM-1] and soluble CD146 [sCD146]), plasminogen activator inhibitor-1 (PAI-1), fetuin-A and hs-CRP were studied. Examinations were performed on attack-free periods. The levels of hs-CRP, fetuin-A, sICAM-1, and PAI-1 were significantly higher in newly diagnosed patients compared to those of controls (P < 0.05). All studied parameters were significantly downregulated after regular colchicine therapy (P < 0.05). Comparison of on-treatment data with controls showed that the levels of the vascular biomarkers, except sCD146, were similar between the groups (P > 0.05). On-treatment sCD146 was found significantly lower than the controls (P < 0.05). In regression analysis, none of the independent variables in the model significantly predicted the vascular biomarkers (P > 0.05). Administration of therapeutic doses of colchicine markedly reduces vascular injury parameters and normalizes the values in FMF.